Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR - PubMed (original) (raw)
Comparative Study
Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR
Thuong Nguyen Thi et al. Antiviral Res. 2006 Mar.
Abstract
An antiviral drug susceptibility assay of herpes simplex virus (HSV) was developed using real-time PCR quantification of intracellular viral DNA load. The number of HSV DNA copies within Vero cells after 24 h infection was strongly correlated with the number of plaques obtained after 72 h infection. Antiviral drug susceptibility of HSV was determined after virus growth for 24h by measuring the reduction of intracellular HSV DNA in the presence of increasing concentrations of either acyclovir (ACV) or foscarnet (PFA). This assay required neither preliminary titration of infectious stock nor follow-up of cytopathic effect. The 50% inhibitory concentrations (IC50s) obtained with 27 isolates of HSV types 1 and 2 by using this test were significantly correlated with those obtained in parallel with plaque reduction assay taken as the reference method (r=0.91, p<0.0001 and r=0.51, p=0.009 for ACV and PFA, respectively). The threshold real-time PCR IC50s for ACV and PFA resistance did not differ according to HSV type and were determined to be 1.0 and 100 microM, respectively. The real-time PCR susceptibility assay reported here is rapid, reproducible, applicable for HSV-1 as well as HSV-2, and suitable for automation.
Similar articles
- Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M, Yasuda Y, Yabe H, Kato S, Suzutani T, De Clercq E, Niikura M, Maeda A, Kurane I, Morikawa S. Saijo M, et al. J Med Virol. 2002 Sep;68(1):99-104. doi: 10.1002/jmv.10175. J Med Virol. 2002. PMID: 12210436 - Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay.
Shiota T, Lixin W, Takayama-Ito M, Iizuka I, Ogata M, Tsuji M, Nishimura H, Taniguchi S, Morikawa S, Kurane I, Mizuguchi M, Saijo M. Shiota T, et al. Antiviral Res. 2011 Aug;91(2):142-9. doi: 10.1016/j.antiviral.2011.05.015. Epub 2011 Jun 2. Antiviral Res. 2011. PMID: 21669227 - Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.
Ziyaeyan M, Alborzi A, Japoni A, Kadivar M, Davarpanah MA, Pourabbas B, Abassian A. Ziyaeyan M, et al. Int J Dermatol. 2007 Dec;46(12):1263-6. doi: 10.1111/j.1365-4632.2007.03449.x. Int J Dermatol. 2007. PMID: 18173520 - [Diagnostic and therapeutic strategy for acyclovir-resistant herpes encephalitis].
Saijo M. Saijo M. Rinsho Shinkeigaku. 2014;54(12):1024-7. doi: 10.5692/clinicalneurol.54.1024. Rinsho Shinkeigaku. 2014. PMID: 25672698 Review. Japanese. - Antiviral properties of 3-quinolinecarboxamides: a series of novel non-nucleoside antiherpetic agents.
Wentland MP, Perni RB, Dorff PH, Brundage RP, Castaldi MJ, Carlson JA, Bailey TR, Aldous SC, Carabateas PM, Bacon ER, Kullnig RK, Young DC, Woods MG, Kingsley SD, Ryan KA, Rosi D, Drozd ML, Dutko FJ. Wentland MP, et al. Drug Des Discov. 1997 May;15(1):25-38. Drug Des Discov. 1997. PMID: 9332829 Review.
Cited by
- Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.
Piret J, Boivin G. Piret J, et al. Antimicrob Agents Chemother. 2011 Feb;55(2):459-72. doi: 10.1128/AAC.00615-10. Epub 2010 Nov 15. Antimicrob Agents Chemother. 2011. PMID: 21078929 Free PMC article. Review. - Natural Products-Derived Chemicals: Breaking Barriers to Novel Anti-HSV Drug Development.
Treml J, Gazdová M, Šmejkal K, Šudomová M, Kubatka P, Hassan STS. Treml J, et al. Viruses. 2020 Jan 29;12(2):154. doi: 10.3390/v12020154. Viruses. 2020. PMID: 32013134 Free PMC article. Review. - Utilization of microsatellite polymorphism for differentiating herpes simplex virus type 1 strains.
Deback C, Boutolleau D, Depienne C, Luyt CE, Bonnafous P, Gautheret-Dejean A, Garrigue I, Agut H. Deback C, et al. J Clin Microbiol. 2009 Mar;47(3):533-40. doi: 10.1128/JCM.01565-08. Epub 2008 Dec 24. J Clin Microbiol. 2009. PMID: 19109460 Free PMC article. - Reduction in severity of a herpes simplex virus type 1 murine infection by treatment with a ribozyme targeting the UL20 gene RNA.
Liu J, Lewin AS, Tuli SS, Ghivizzani SC, Schultz GS, Bloom DC. Liu J, et al. J Virol. 2008 Aug;82(15):7467-74. doi: 10.1128/JVI.02720-07. Epub 2008 May 28. J Virol. 2008. PMID: 18508896 Free PMC article. - A cluster randomised trial of cloth masks compared with medical masks in healthcare workers.
MacIntyre CR, Seale H, Dung TC, Hien NT, Nga PT, Chughtai AA, Rahman B, Dwyer DE, Wang Q. MacIntyre CR, et al. BMJ Open. 2015 Apr 22;5(4):e006577. doi: 10.1136/bmjopen-2014-006577. BMJ Open. 2015. PMID: 25903751 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources